Filing Details

Accession Number:
0001209191-22-044621
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-05 18:01:25
Reporting Period:
2022-08-03
Accepted Time:
2022-08-05 18:01:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1630627 Treace Medical Concepts Inc. TMCI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1188309 E Thomas Timbie 203 Ft Wade Road
Suite 150
Ponte Vedra FL 32081
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-08-03 96,879 $18.85 1,552,190 No 4 S Indirect Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001
Common Stock Disposition 2022-08-04 48,217 $18.56 1,503,973 No 4 S Indirect Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001
Common Stock Disposition 2022-08-05 4,904 $19.04 1,499,069 No 4 S Indirect Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001
No 4 S Indirect Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001
No 4 S Indirect Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,295 Direct
Common Stock 385,000 Indirect Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.17 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.91 to $19.34 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date.